Filing Flows › Interpace Biosciences (IDXG) › Q1 2026
Interpace Biosciences (IDXG) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
Interpace Biosciences (IDXG) reported revenue of $9.0M for the first quarter 2026 (Q1 2026), -22% from a year earlier and -2% from the quarter before. Operating margin was 12.4%, net earnings $721K (8.0% of revenue).
Interpace Biosciences, Q1 2026: revenue $9.0M (-22% year over year), operating margin 12.4%, net earnings $721K, operating cash flow $283K. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.0M | -2% | -22% |
| Gross profit | $5.9M | -2% | -20% |
| Operating profit | $1.1M | -29% | -39% |
| Net earnings | $721K | -97% | -56% |
| Operating cash flow | $283K | -87% | -77% |
| Free cash flow | $142K | -93% | — |
What changed
Revenue was $9.0M in Q1 2026, down 22% year over year and down 2% from the previous quarter.
Gross margin was 65.4%, up 1.4 points from Q1 2025. Operating profit was $1.1M, a 12.4% margin (down 3.5 points year over year). Operating expenses fell 14% while revenue fell 22%. Net earnings were $721K, down 56% year over year. The effective tax rate was 29.5%.
Operating cash flow was $283K (down 77% year over year), 39% of net earnings. Non-cash charges added back $118K of depreciation and amortization and $4K of share-based compensation. Working capital and other items used $560K. Capital expenditures of $141K left free cash flow of $142K.
Questions
What was Interpace Biosciences' revenue in the first quarter 2026?
Interpace Biosciences (IDXG) reported revenue of $9.0M for the first quarter 2026 (Q1 2026), -22% from a year earlier and -2% from the quarter before.
Was Interpace Biosciences profitable in the first quarter 2026?
Operating profit was $1.1M (12.4% of revenue) and net earnings $721K.